Zevra Therapeutics
Zevra Therapeutics' revenue rose 350.9% to $106 million in fiscal 2025. Its operating margin was −59.1%, up from −368.5% a year earlier. Free cash flow was −$2 million. The diluted share count rose 23.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Zevra Therapeutics does
Zevra Therapeutics sells medicines for rare diseases. Its main product is MIPLYFFA (arimoclomol), which the FDA approved in September 2024, used with miglustat, for the neurological symptoms of Niemann-Pick disease type C (NPC), a rare, progressive nerve disease. It went on sale in the United States in November 2024. It also sells OLPRUVA, an oral suspension that came with its 2023 purchase of Acer Therapeutics.
Nearly all of its revenue comes from one product. Zevra says it is seeking approval in the European Union, where it filed an application in July 2025 that is under review. It also develops celiprolol, a drug candidate in clinical trials, and says it plans to add to its pipeline by acquiring assets.
With the FDA approval it received a priority review voucher, a transferable right to a faster review of a future drug. It sold the voucher on April 1, 2025, for net proceeds of $148.3 million. In 2022 it bought the arimoclomol assets and operations of Orphazyme A/S.
Its biggest risks, as it describes them
- It depends on one product for substantially all of its revenues, so losing that revenue would hurt it badly.
- The patient groups for its products are small, so it needs a large share of patients to make money.
- It may not build effective sales, marketing and distribution for its approved products.
- Insurers and other payors may refuse coverage or pay too little for its products.
- It has had negative operating cash flows throughout its history and cannot say when that will change.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 112 | 82 | 68 | 70 | 191 |
| Debt incl. finance leases | 0 | 0 | 5 | 60 | 62 |
| Net debt (negative means net cash) | −112 | −82 | −63 | −10 | −129 |
| Net debt to EBITDA | −14.1x | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.1x | 1.5x | 0.4x |
| Interest coverage | 34.2x | −127.1x | −33.0x | −11.8x | −7.9x |
| Current ratio | 27.2x | 7.7x | 1.2x | 2.5x | 5.7x |
| Quick ratio | 27.2x | 7.7x | 1.2x | 2.5x | 5.6x |
Cash flow
Projections
Project Zevra Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Zevra Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 2 of 8 | 5 of 8 |
| Rule of 40 | 47.1% | −309.1% | 348.6% |
| Altman Z'' | −8.41 | −10.32 | −0.84 |
| Accruals ratio | −8.7% | −20.5% | 36.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 2 of 9 | 2 of 8 | 5 of 8 |
Compare
Put Zevra Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Zevra Therapeutics | FY25 | 350.9% | −59.1% | −2.3% | −218.8% | — | 5 | |
| Zymeworks | FY25 | 38.9% | −87.3% | −32.6% | — | — | — | Compare |
| UroGen Pharma | FY25 | 21.4% | −113.7% | −148.2% | — | — | 2 | Compare |
| Nurix Therapeutics | FY25 | 54.0% | −340.2% | −313.7% | — | — | — | Compare |
| Eton Pharmaceuticals | FY25 | 104.9% | −1.1% | 12.8% | −1.9% | 1.4x | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | 0 | 13 | 13 | 29 | 10 | 28 | 24 | 106 |
| Revenue growth | — | — | — | — | 3.5% | 115.6% | −64.5% | 170.3% | −14.0% | 350.9% |
| Gross profit | — | — | 0 | 3 | — | 27 | 10 | 24 | — | — |
| Research and development | 20 | 21 | 42 | 19 | 9 | 10 | 20 | 40 | 42 | 13 |
| Operating income | −38 | −33 | −56 | −20 | −6 | 8 | −43 | −50 | −87 | −63 |
| Net income | −16 | −43 | −56 | −24 | −13 | −9 | −27 | −46 | −106 | 83 |
| Diluted EPS (US$) | −1.13 | −2.96 | −3.15 | −13.23 | −3.21 | −2.11 | — | — | −2.28 | 1.35 |
| Diluted shares (millions) | 15 | 15 | 18 | 2 | 4 | 30 | 34 | 36 | 46 | 57 |
| Cash flow | ||||||||||
| Cash from operations | −30 | −33 | −54 | −24 | −2 | 10 | −19 | −34 | −70 | −2 |
| Capital expenditure | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Free cash flow | −30 | −33 | −54 | −24 | −2 | 10 | −19 | −34 | −70 | −2 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 3 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 30 | 0 | 0 |
| Stock-based compensation | 7 | 5 | 6 | 4 | 2 | 2 | 4 | 6 | 15 | 13 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 68 | 42 | 22 | — | 4 | 112 | 82 | 68 | 70 | 191 |
| Debt incl. finance leases | 91 | 93 | 81 | 78 | 68 | 0 | 0 | 5 | 60 | 62 |
| Total assets | 85 | 52 | 27 | 10 | 11 | 133 | 115 | 172 | 178 | 285 |
| Total liabilities | 104 | 110 | 93 | 85 | 78 | 6 | 40 | 110 | 138 | 130 |
| Shareholders' equity | −19 | −58 | −67 | −74 | −66 | 102 | 75 | 62 | 40 | 155 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | 22.1% | — | 92.8% | 97.8% | 89.3% | — | — |
| Operating margin | — | — | — | −158.4% | −42.2% | 27.0% | −418.9% | −180.6% | −368.5% | −59.1% |
| Net margin | — | — | — | −191.0% | −96.0% | −29.9% | −263.5% | −167.7% | −446.9% | 78.2% |
| Free cash flow margin | — | — | — | −185.1% | −14.8% | 36.1% | −185.1% | −123.2% | −295.0% | −2.3% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | −11.3% | 151.7% | −249.7% | 47.1% | −309.1% | 348.6% |
| Return on capital | — | — | — | — | — | — | — | — | — | −218.8% |
| Return on equity | — | — | — | — | — | −48.5% | −30.3% | −67.2% | −207.8% | 85.7% |
| Return on assets | −23.7% | −63.2% | −142.6% | −131.7% | −117.5% | −11.9% | −21.6% | −32.0% | −60.2% | 36.0% |
| Net debt to EBITDA | — | — | — | — | — | −14.1x | — | — | — | — |